(Q51303693)

English

Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.

scientific article published on 30 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Guang Ning

1

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Weiqing Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Ling Li

3

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Jianhua Ma

4

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Xiaofeng Lv

5

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Ming Yang

6

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Wei Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Michael Woloschak

8

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Valentina Lukashevich

9

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Wolfgang Kothny

10

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

publication date

30 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Journal of diabetes

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

8

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

3

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

345-353

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Beta-cell function and insulin sensitivity at various degrees of glucose tolerance in Chinese subjects.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Diabetes in Asia: epidemiology, risk factors, and pathophysiology

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Epidemic obesity and type 2 diabetes in Asia

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Do race and ethnicity impact hemoglobin A1c independent of glycemia?

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Deriving ethnic-specific BMI cutoff points for assessing diabetes risk

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Managing diabetes in Asia: overcoming obstacles and the role of DPP-IV inhibitors

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Effect of insulin glargine on glycaemic control and weight in obese and non-obese people with type 2 diabetes: data from the AT.LANTUS trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12303

21 January 2018

Identifiers

10.1111/1753-0407.12303

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/25929739

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51303693&oldid=1197013465"